Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Gene Therapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/cgt.2011.43PMID 21836632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Role of cell surface molecules and autologous ascitic fluid in determining efficiency of adenoviral transduction of ovarian cancer cells

  2010cited by this paper
• Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.

  2010cited by this paper
• Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter

  2009cited by this paper
• Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy.

  2009cited by this paper
• A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984.

  2009cited by this paper
• Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.

  2009cited by this paper
• Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model.

  2009cited by this paper
• A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984].

  2009cited by this paper
• Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo

  2008cited by this paper
• Augmentation of erythropoietin enhancer-mediated hypoxia-inducible gene expression by co-transfection of a plasmid encoding hypoxia-inducible factor 1alpha for ischemic tissue targeting gene therapy.

  2008cited by this paper
• Augmentation of erythropoietin enhancer-mediated hypoxia-inducible gene expression by co-transfection of a plasmid encoding hypoxia-inducible factor 1α for ischemic tissue targeting gene therapy

  2008cited by this paper
• Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy.

  2007cited by this paper
• Targeting tumors with hypoxia-activated cytotoxins.

  2007cited by this paper
• Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards

  2007cited by this paper
• Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4.

  2007cited by this paper
• Evaluation of hypoxia-mediated growth factors in a novel bladder cancer animal model.

  2007cited by this paper
• Hypoxia in cancer: significance and impact on clinical outcome

  2007cited by this paper
• Comparative effects of hypoxia on normal and immortalized human diploid fibroblasts.

  2006cited by this paper
• Cancer gene-therapy: clinical trials.

  2006cited by this paper
• Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.

  2006cited by this paper
• Transcriptional targeting of acute hypoxia in the tumour stroma is a novel and viable strategy for cancer gene therapy

  2005cited by this paper
• Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells.

  2005cited by this paper
• Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors

  2005cited by this paper
• Late Expression of Nitroreductase in an Oncolytic Adenovirus Sensitizes Colon Cancer Cells to the Prodrug CB1954

  2005cited by this paper
• Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.

  2004cited by this paper
• Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector

  2004cited by this paper
• Induction of glucose transporter 1 expression through hypoxia-inducible factor 1alpha under hypoxic conditions in trophoblast-derived cells.

  2004cited by this paper
• Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.

  2003cited by this paper
• Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells

  2003cited by this paper
• How to overcome (and exploit) tumor hypoxia for targeted gene therapy

  2003cited by this paper
• Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells.

  2002cited by this paper
• Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy.

  2002cited by this paper
• Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.

  2002cited by this paper
• Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy.

  2002cited by this paper
• Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives

  2001cited by this paper
• Exposures and outcomes of children with urticaria seen in a pediatric practice-based research network: a case-control study.

  2001cited by this paper
• Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells

  2001cited by this paper
• Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells.

  2000cited by this paper
• Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.

  2000cited by this paper
• Prodrug activation enzymes in cancer gene therapy

  2000cited by this paper
• Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector‐mediated expression of E. coli nitroreductase

  2000cited by this paper
• Insulation of a conditionally expressed transgene in an adenoviral vector

  1999cited by this paper
• Trends in cancer incidence and mortality in Scotland: description and possible explanations.

  1998cited by this paper
• Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro.

  1998cited by this paper
• United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition).

  1998cited by this paper
• Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter.

  1996cited by this paper
• Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA.

  1991cited by this paper

• Suicide gene strategies applied in ovarian cancer studies

  2023influential citation
• Hypoxia-directed tumor targeting of CRISPR-Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles

  2022cites this paper
• Hypoxia-directed tumor targeting of CRISPR/Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles

  2021cites this paper
• Pursuing for the better lung cancer therapy effect: Comparison of two different kinds of hyaluronic acid and nitroimidazole co-decorated nanomedicines.

  2020cites this paper
• Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and in vivo

  2017cites this paper
• Cell physiology regulation by hypoxia inducible factor-1: Targeting oxygen-related nanomachineries of hypoxic cells.

  2017cites this paper
• Applications of the Keap1-Nrf2 system for gene and cell therapy.

  2015cites this paper
• Lentivirus-mediated RASSF1A expression suppresses aggressive phenotypes of gastric cancer cells in vitro and in vivo

  2015cites this paper
• Structural basis of Escherichia coli nitroreductase NfsB triple mutants engineered for improved activity and regioselectivity toward the prodrug CB1954

  2015cites this paper
• A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.

  2014cites this paper
• Gene Therapy Used in Cancer Treatment

  2014cites this paper
• TARGETING RETINAL NEOVASCULARIZATION 2

  2014cites this paper
• Regulated expression systems for gene therapy

  2013cites this paper
• The nitroreductase system of inducible targeted ablation facilitates cell-specific regenerative studies in zebrafish.

  2013cites this paper
• Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954.

  2012cites this paper
• Suicide gene therapy in cancer: where do we stand now?

  2012cites this paper
• Adenovirus vectors with modified tropism for the treatment of colorectal cancer

  2012cites this paper
• Photoinduced ligand exchange and covalent DNA binding by two new dirhodium bis-amidato complexes.

  2012cites this paper
• microRNA and the pathogenesis of ovarian cancer – a new horizon for molecular diagnostics and treatment?

  2012cites this paper
• Virus Adaptation and Treatment The impact of hypoxia on oncolytic virotherapy

  2011cites this paper
• The impact of hypoxia on oncolytic virotherapy

  2011cites this paper
• Regulation of the prostate-specific hTGP (TGM4) gene and its potential use for prostate cancer gene therapy

  2011cites this paper
• AN OVERVIEW OF GENE THERAPY USED IN CANCER TREATMENT

  year unknowncites this paper